Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABCHIX:ALIFBS 86 Return-on-Tangible-Asset is 9.53% as of Jun. 2026, which is 25% below its 10-year median of 12.65. GuruFocus rates CHIX:ALIFBS with a GF Score™ of 86/100 and a GF Value™ of kr147.90 (Fairly Valued). The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, AddLife AB ranks better than 86.2% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AddLife AB's annualizedNet Income for the quarter that ended in Jun. 2026 was kr520 Mil. AddLife AB's average total tangible assets for the quarter that ended in Jun. 2026 was kr5,459 Mil. Therefore, AddLife AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 9.53%.
The historical rank and industry rank for AddLife AB's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:ALIFBs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.04 Med: 12.65 Max: 28.29
Current: 11.4
During the past 13 years, AddLife AB's highest Return-on-Tangible-Asset was 28.29%. The lowest was 4.04%. And the median was 12.65%.
CHIX:ALIFBs's Return-on-Tangible-Asset is ranked better than 86.2% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs CHIX:ALIFBs: 11.40
AddLife AB (CHIX:ALIFBs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
AddLife AB Return-on-Tangible-Asset Related Terms
AddLife AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for AddLife AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALIFBS vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, AddLife AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where AddLife AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.53% mean?
AddLife AB (CHIX:ALIFBS) has a Return-on-Tangible-Asset of 9.53% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AddLife AB and its competitors. This is 25% below median its historical median of 12.65. Over the past decade, AddLife AB's Return-on-Tangible-Asset has ranged from 4.04 to 28.29. According to the industry distribution chart, AddLife AB ranks #118 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is AddLife AB's Return-on-Tangible-Asset too high?
AddLife AB's current Return-on-Tangible-Asset of 9.53% is 25% below median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 4.04 to a high of 28.29. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.56. AddLife AB's value of 9.53% is 1601.8% above this industry median. Based on the distribution chart, AddLife AB ranks #118 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AddLife AB has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #118 out of 855 companies for Return-on-Tangible-Asset. This places AddLife AB in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.56. AddLife AB's value of 9.53% is 1601.8% above this benchmark. Historically, AddLife AB's own Return-on-Tangible-Asset has ranged from 4.04 to 28.29 over the past decade. While the company's 10-year median is 12.65 vs. the industry median of 0.56, AddLife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.56, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current Return-on-Tangible-Asset of 9.53% is 1601.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current Return-on-Tangible-Asset is 9.53%, which is 25% below median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
Based on GuruFocus' analysis, AddLife AB (CHIX:ALIFBS) is currently considered Fairly Valued. The stock's GF Value™ is kr147.90, compared to a current price of kr159.05 — trading 7.5% above its estimated fair value. The current Return-on-Tangible-Asset is 9.53%, which is 25% below median its 10-year median of 12.65 and 1601.8% above the Medical Devices & Instruments industry median of 0.56. AddLife AB's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For AddLife AB (CHIX:ALIFBS), the current Return-on-Tangible-Asset is 9.53% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (CHIX:ALIFBS) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of kr159.05 is trading 7.5% above its estimated GF Value™ of kr147.90.
GuruFocus considers AddLife AB to be Fairly Valued.
Key valuation signals for CHIX:ALIFBS:
Return-on-Tangible-Asset: 9.53% (25% below median its 10-year median of 12.65)
GF Value™: kr147.90 vs. price of kr159.05 (7.5% above fair value)
Industry Position: 1601.8% above the Medical Devices & Instruments median (#118 of 855)
No single metric tells the full story. See the CHIX:ALIFBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
86GF Score
Get the complete analysis for CHIX:ALIFBS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALIFBS has been successfully added to your 
